This property of UHRF1 targeting may be conducive to development of efficient combination therapies as it would improve the efficacy and selectivity of conventional chemotherapy regimens composed of nontargeted drugs against tumor cells without a risk of complications involved in DNA methylation. This evidence concerns the gene UHRF1 and neoplasm.